Criterion #,Criterion,Max Score,Satisfaction (%),Score Awarded,Rationale
1,"Reward for accurately documenting the patient's current symptom report, including increased rheumatoid arthritis pain severity, day-to-day variability, and uncertainty about hydroxychloroquine benefit",15,75.0,11.25,"Captures increased pain intensity, day-to-day variability (""some days are better than others""), and uncertainty about HCQ benefit, but lacks explicit numeric severity or duration detail."
2,"Reward for clearly listing all current rheumatoid arthritis medications with exact doses (methotrexate 15 mg weekly, hydroxychloroquine 200 mg daily, folic acid 1 mg daily) and noting adherence to folic acid",15,0.0,0.0,"No medication list, doses, or note of folic acid adherence provided."
3,Reward for capturing the shared decision-making discussion about potential DMARD dose adjustment or alternative therapy and specifying a concrete follow-up monitoring plan,15,0.0,0.0,"No discussion of dose adjustment, alternative therapy, or follow-up monitoring documented."
4,"Reward for delineating an evidence-based rheumatoid arthritis management strategy consistent with ACR guidelines, such as allowing an adequate trial period before escalation and outlining options for dose increase or additional DMARD/biologic",15,0.0,0.0,"No management strategy, escalation timeline, or options per ACR guidelines included."
5,"Penalize for failure to document necessary patient safety monitoring related to methotrexate and hydroxychloroquine, including baseline and periodic CBC/LFTs and scheduling of ophthalmology screening",15,0.0,0.0,Fails to mention any CBC/LFT or ophthalmology monitoring; complete omission.
6,Reward for documenting the patient's sulfa drug allergy in the note,10,0.0,0.0,Sulfa allergy not documented anywhere in note.
7,"Reward for using appropriate Canvas instruction tags that correctly categorize each data element (e.g., Assess for RA, AdjustPrescription if dose change, FollowUp for revisit)",5,60.0,3.0,"Uses correct HPI and Assess commands for RA; however, omits other relevant tags (AdjustPrescription, FollowUp)."
8,Penalize for inclusion of redundant chart information or excessive verbiage not pertinent to this encounter segment,10,90.0,9.0,Note is brief without redundant chart data or unnecessary verbiage.
